Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.
Key findings
94% of Americansestimated infected with the virus at least once by November 2022; 65% more than once
By late 2022, nearly every American had caught COVID-19 at least once.
A national model of US case, hospitalization and vaccination data estimated that by November 2022, 94% of people in the US had been infected at least once and 65% more than once. From December 2021 to November 2022 alone, it estimated 209 million reinfections versus 116 million first infections.
Reinfection, not first infection, became the usual way Americans met the virus. The authors note that waning immunity or a new variant could still fuel fresh waves despite this widespread exposure. These are model estimates built from reported data and assumptions, with wide uncertainty (79% to 99% ever infected), not antibody tests of every person.
A Bayesian modeling study combining CDC case, hospitalization and vaccination data for every US state and county, from December 2021 to November 2022.
From the study: “By 9 November 2022, 94% (95% CrI: 79%–99%) of the US population were estimated to have been infected by SARS-CoV-2 at least once”
94% of Americans
Klaassen F et al. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
From the study: “65% (35%–88%) were estimated to have experienced multiple infections over the course of the pandemic”
94% of Americans
Klaassen F et al. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
From the study: “Between 2 December 2021 and 9 November 2022, 116 (67–135) million first infections were estimated to have occurred, and 209 (118–292) million reinfections”
94% of Americans
Klaassen F et al. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
About 1 in 16,000infected healthy Danish adults aged 17–72 died within 30 days in the Omicron wave
Death risk per Omicron infection was far below earlier waves in Denmark.
Using antibody tests on blood donors linked to national registers, researchers estimated that 66% of healthy Danish adults were infected between November 2021 and March 2022. About 6.2 per 100,000 infected people died within 30 days, far below estimates from previous Danish waves, such as 74.1 per 100,000.
For healthy working-age adults, the chance of dying from an Omicron infection was a small fraction of the early pandemic's. The study also found about one third of infections never showed up in PCR test counts. Donors were healthy, mostly vaccinated adults aged 17–72 with no known illnesses, so this rate does not apply to older or chronically ill people.
A nationwide Danish blood-donor antibody survey of about 35,000 donors aged 17–72, linked to national health registers, from November 2021 to April 2022.
From the study: “Infection fatality rate was low with a 30-day mortality of 6·2 (CI: 5·1–7·5) per 100 000 infections.”
About 1 in 16,000
Erikstrup C et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. The Lancet regional health. Europe. 2022.
From the study: “we estimate that 66% (CI: 63%–70%) of the healthy adult Danish population were infected with SARS-CoV-2 between November 1, 2021, and March 15, 2022”
About 1 in 16,000
Erikstrup C et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. The Lancet regional health. Europe. 2022.
From the study: “The IFR was considerable lower than the IFRs calculated during previous waves in Denmark, with 30-day mortalities of 74·1”
About 1 in 16,000
Erikstrup C et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. The Lancet regional health. Europe. 2022.
35% fewer cases at 60+symptomatic infections with surgical masks, ages 60+ (adjusted prevalence ratio 0.65)
Surgical mask promotion cut symptomatic COVID-19 by 35% in people 60-plus.
In a trial in rural Bangladesh, villages randomly assigned to receive masks and promotion saw proper mask-wearing rise to 42.3%, versus 13.3% in control villages. Where surgical masks were handed out, symptomatic infections confirmed by antibody tests fell 11% overall and 35% among people 60 and older, compared with control villages.
This is one of the few large randomized trials of masks in everyday community life. The benefit was biggest for older adults, who face the highest death risk, while cloth masks showed a smaller, uncertain effect. Done in rural Bangladesh from late 2020 to early 2021, before vaccines, and only about 40% of people with symptoms agreed to give blood for testing.
A cluster-randomized trial in 600 villages in rural Bangladesh with about 342,000 adults, November 2020 to April 2021, comparing mask distribution and promotion with no intervention.
From the study: “Proper mask-wearing increased from 13.3% in the control group to 42.3% in the intervention arm”
35% fewer cases at 60+
Abaluck J et al. Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. Science (New York, N.Y.). 2022.
From the study: “the relative reduction in symptomatic seroprevalence was 11% overall, 23% among individuals aged 50 to 59 years, and 35% among those ≥60 years of age”
35% fewer cases at 60+
Abaluck J et al. Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. Science (New York, N.Y.). 2022.
From the study: “especially among adults ≥60 years old in villages where surgical masks were distributed (adjusted prevalence ratio = 0.65 [0.45, 0.85])”
35% fewer cases at 60+
Abaluck J et al. Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh. Science (New York, N.Y.). 2022.
1 in 100 at age 60of infected people died in the pre-vaccine era; about 1 in 5 at age 90
Before vaccines, COVID-19's death risk climbed steeply with every decade of age.
Matching thousands of antibody surveys worldwide to COVID-19 death counts, researchers estimated the share of infected people who died before vaccines. Risk was lowest at age 7, then rose exponentially: about 1.0% at age 60 and 20.3% at age 90. Even before vaccines, the typical risk fell 33% over 8 months.
A 60-year-old faced roughly a 1 in 100 chance of dying if infected, and a 90-year-old about 1 in 5. The authors suggest the early decline reflected improving treatment. These 2020 pre-vaccine estimates fell sharply later, and an analysis limited to national surveys found lower risks for non-elderly adults.
A global systematic analysis matching 2,073 all-age and 718 age-specific antibody surveys to COVID-19 deaths across 190 countries and territories, April 2020 to January 2021.
From the study: “increasing exponentially through ages 30 years (0·0573%, 0·0418-0·0870), 60 years (1·0035%, 0·7002-1·5727), and 90 years (20·3292%, 14·6888-28·9754)”
1 in 100 at age 60
COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet (London, England). 2022.
From the study: “The lowest IFR occurred at age 7 years and IFR increased in an approximately log-linear fashion among ages older than 30 years”
1 in 100 at age 60
COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet (London, England). 2022.
From the study: “the estimated 33% decrease in median IFR over 8 months suggests that treatment for COVID-19 has improved over time”
1 in 100 at age 60
COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet (London, England). 2022.
59% of spreadcame from people with no symptoms at the time, in a CDC model's baseline scenario
Over half of COVID-19 spread likely came from people without symptoms.
A CDC model estimated that, in its baseline scenario, 59% of transmission came from people without symptoms: 35% from people who had not yet developed symptoms and 24% from people who never would. Across a broad range of assumptions, at least 50% of new infections came from people without symptoms.
Isolating only sick people cannot stop most spread. The authors pointed to masks, distancing, hand hygiene and testing people who feel well as the foundations of control. This is a model built on assumptions from early-pandemic studies, not direct observation, and the shares may differ for later variants or vaccinated people.
A CDC decision-analysis model published in 2021 that varied published estimates of symptom-free infection and infectious timing to estimate who drives transmission.
From the study: “In this base case, 59% of all transmission came from asymptomatic transmission, comprising 35% from presymptomatic individuals and 24% from individuals who never develop symptoms.”
59% of spread
Johansson MA et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA network open. 2021.
From the study: “at least 50% of new SARS-CoV-2 infections was estimated to have originated from exposure to individuals with infection but without symptoms”
59% of spread
Johansson MA et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA network open. 2021.
1 in 8 infected adultshad lasting symptoms 90–150 days on, beyond rates in matched uninfected people
About 1 in 8 infected adults had lasting symptoms tied to COVID-19.
In a Dutch population study tracking symptoms before and after infection, 21.4% of adults with COVID-19 had at least one core symptom, such as tiredness, chest pain or trouble breathing, newly worsened to at least moderate at 90–150 days, versus 8.7% of matched people without COVID-19. The 12.7% difference was attributed to COVID-19.
Many long COVID estimates count symptoms people already had or that uninfected people also report. Subtracting both still left a sizable group whose tiredness, breathing trouble or muscle pain appeared after infection and persisted. Participants were mostly White adults in the northern Netherlands infected in 2020–2021, before most were vaccinated, and brain fog was not measured.
A population cohort of 76,422 Dutch adults answering repeated symptom surveys from March 2020 to August 2021; 4,231 who got COVID-19 were compared with 8,462 matched uninfected people.
From the study: “381 (21·4%) of 1782 COVID-19-positive participants versus 361 (8·7%) of 4130 COVID-19-negative controls”
1 in 8 infected adults
Ballering AV et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet (London, England). 2022.
From the study: “substantially increased to at least moderate severity at 90-150 days after COVID-19 diagnosis or matched timepoint”
1 in 8 infected adults
Ballering AV et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet (London, England). 2022.
From the study: “In 12·7% of patients, these symptoms could be attributed to COVID-19”
1 in 8 infected adults
Ballering AV et al. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet (London, England). 2022.
About 1 in 5 casesseeded 80% of all local spread in Hong Kong's early 2020 outbreak
About 1 in 5 infected people seeded 80% of COVID-19 spread.
Contact tracing of 1,038 confirmed cases in Hong Kong found that 19% of cases seeded 80% of all local transmission. Spread in social settings was linked to more secondary cases than spread within households, and being quarantined as a contact was linked to 14.4-fold higher odds of transmission being interrupted.
When a few people in social gatherings drive most spread, targeting those settings and rapidly quarantining contacts can prevent far more infections than treating every case the same. This reflects early 2020 in Hong Kong with intensive contact tracing, before newer variants and vaccines, so the exact share may differ elsewhere.
An analysis of contact-tracing records for 1,038 confirmed COVID-19 cases in Hong Kong from January to April 2020, grouped into transmission clusters.
From the study: “estimated that 19% (95% confidence interval, 15-24%) of cases seeded 80% of all local transmission”
About 1 in 5 cases
Adam DC et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nature medicine. 2020.
From the study: “Using contact tracing data from 1,038 SARS-CoV-2 cases confirmed between 23 January and 28 April 2020 in Hong Kong”
About 1 in 5 cases
Adam DC et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nature medicine. 2020.
From the study: “although the odds that an individual being quarantined as a contact interrupted transmission was 14.4”
About 1 in 5 cases
Adam DC et al. Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong. Nature medicine. 2020.
39% fewer school casesin Georgia elementary schools that improved ventilation, versus those that did not
Elementary schools with better ventilation had 39% fewer COVID-19 cases.
In 169 Georgia elementary schools open in fall 2020, COVID-19 incidence among students and staff was 39% lower in schools that improved ventilation and 37% lower where teachers and staff had to wear masks, versus schools without these steps. Opening windows, doors or using fans alone was linked to 35% lower incidence; combined with filtration such as HEPA filters, 48% lower.
Ventilation and filtration are building fixes that do not rely on children's behavior. In this study, requiring students to mask showed a smaller difference that was not statistically clear. Observational rate ratios from the 11.6% of contacted schools that responded, before vaccines, so other differences between schools may explain part of the gap.
A CDC and Georgia health department survey of 169 elementary schools, linked to cases reported from November 16 to December 11, 2020.
From the study: “COVID-19 incidence was 37% lower in schools that required teachers and staff members to use masks and 39% lower in schools that improved ventilation.”
39% fewer school cases
Gettings J et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools - Georgia, November 16-December 11, 2020. MMWR. Morbidity and mortality weekly report. 2021.
From the study: “Ventilation strategies associated with lower school incidence included dilution methods alone (35% lower incidence) or in combination with filtration methods (48% lower incidence).”
39% fewer school cases
Gettings J et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools - Georgia, November 16-December 11, 2020. MMWR. Morbidity and mortality weekly report. 2021.
From the study: “Among 169 K–5 schools that participated in a survey on prevention strategies and reported COVID-19 cases during November 16–December 11, 2020”
39% fewer school cases
Gettings J et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools - Georgia, November 16-December 11, 2020. MMWR. Morbidity and mortality weekly report. 2021.
Study-specific findings. Different populations, treatments and follow-up periods can produce different results.
The infection-related antibody boost declined over follow-up
48%
In unvaccinated, HIV-uninfected Malawi participants, 48% of the acute neutralising-antibody boost remained three months after infection and 5% remained one year after infection.
The assay used pseudotyped virus. These are changes in the antibody boost, not percentages of people protected from illness; the study does not directly establish clinical protection.
Infection reconstruction depended on antibody methods and location
The model identified infections missed by traditional antibody-change thresholds. Estimated infection incidence was higher in urban Lilongwe than rural Karonga during the early 2022 Omicron wave.
The Malawi study involved unvaccinated, HIV-uninfected participants. Infection histories depended on model assumptions and pseudotyped-virus assays, rather than direct clinical confirmation of every inferred infection.
Study details & original results
McCormack, Mhairi J et al.. SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi.. PLOS global public health. 2026.
Proportion of the acute neutralising-antibody boost remaining three months after infection
48% 0.403-0.560 (interval type not specified in the abstract)
Proportion of the acute neutralising-antibody boost remaining one year after infection
5% 0.027-0.098 (interval type not specified in the abstract)
Wastewater captured broader viral diversity in the Georgia comparison
2,218 vs 135 SARS-CoV-2 lineages/sub-lineages
In corresponding Georgia sewersheds, wastewater detected 2,218 SARS-CoV-2 lineages or sub-lineages versus 135 in clinical specimens.
January 2023-July 2024: 669 wastewater samples versus 325 clinical specimens. This descriptive comparison has unequal sample counts and is not an estimate of personal infection risk or per-sample detection performance.
Study details & original results
Yu, Harrison et al.. Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024.. Microbiology spectrum. 2026.
Georgia, January 2023-July 2024: lineages detected in 669 wastewater samples versus 325 clinical specimens from corresponding sewersheds; descriptive comparison with unequal sample counts.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
Browse all 5 recorded findingsSearch the original results, comparisons and study details.
2 of 2 source groupsFindings stay together with their study.
SOURCE 094 findings
McCormack, Mhairi J et al.. SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi.. PLOS global public health. 2026.
Proportion of model-identified infections not detected by traditional seroconversion-based thresholds
Added
39 infections (9.1%)No interval reported for 9.1%; total modeled infections were 429 (95% credible interval: 417-441)Source [9]
Seroincidence in urban Lilongwe versus rural Karonga, driven by the early 2022 Omicron wave
Added
0.41 vs 0.27 infections per person per three monthsSource [9]
All 4 findings from this source
Proportion of the acute neutralising-antibody boost remaining three months after infection
Added
48%0.403-0.560 (interval type not specified in the abstract)Source [9]
Proportion of the acute neutralising-antibody boost remaining one year after infection
Added
5%0.027-0.098 (interval type not specified in the abstract)Source [9]
SOURCE 081 finding
Yu, Harrison et al.. Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024.. Microbiology spectrum. 2026.
Georgia, January 2023-July 2024: lineages detected in 669 wastewater samples versus 325 clinical specimens from corresponding sewersheds; descriptive comparison with unequal sample counts.
Added
2,218 vs 135 SARS-CoV-2 lineages/sub-lineagesSource [8]
Browse the 17 original sourcesThe complete bibliography behind this monitor.
[1]
Parker, Edward P K et al.. Factors associated with severe COVID-19 in immunocompromised subgroups in England from 2020 to 2024: an OpenSAFELY cohort study.. EBioMedicine. 2026.
Mikdashi, Fatima et al.. Estimating the Quality-Adjusted Life-Year Loss due to Fatal and Nonfatal COVID-19 Outcomes across US States and Counties, July 2020 to December 2022.. MDM policy & practice. 2026.
SeyedAlinaghi, SeyedAhmad et al.. Risk Factors of the Spread of COVID-19 in Prisoners: A Systematic Review and Meta-Analysis.. Disaster medicine and public health preparedness. 2026.
Hassan, Abdullah et al.. Seroprevalence convergence masks persistent socioeconomic disparities in SARS-CoV-2 infection risk in Canada.. Epidemics. 2026.
Gravenstein, Stefan et al.. Current Impact of COVID-19 in Long-Term Care Facilities in the United States: A Systematic Literature Review.. The Senior care pharmacist. 2026.
Song, PingPing et al.. Mapping spatial colleague connectivity patterns from individual-level registry data to inform regional pandemic interventions.. PLoS computational biology. 2026. [Source notice: Version 2; publisher new-version event 2026-09-11. The HTML text supporting these two findings matches the earlier proof; other article changes were not exhaustively assessed.]
Smith, Teresa C et al.. Association of SARS-CoV-2 Positivity in Travelers and Community Prevalence: Serial Cross-Sectional Data From the Traveler-based Genomic Surveillance Program.. Public health reports (Washington, D.C. : 1974). 2026.
Yu, Harrison et al.. Wastewater-based genomic surveillance uncovers broader SARS-CoV-2 diversity and spatial transmission dynamics in Georgia, January 2023-July 2024.. Microbiology spectrum. 2026.
McCormack, Mhairi J et al.. SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi.. PLOS global public health. 2026.
Klaassen F et al. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023.
Erikstrup C et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study. The Lancet regional health. Europe. 2022.
COVID-19 Forecasting Team. Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet (London, England). 2022.
Gettings J et al. Mask Use and Ventilation Improvements to Reduce COVID-19 Incidence in Elementary Schools - Georgia, November 16-December 11, 2020. MMWR. Morbidity and mortality weekly report. 2021.
Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.